Observational, prospective study to examine association values of Interferon-Gamma Release Assay (IGRA) before and after treatment and clinical response or adverse events in patients with lung cancer who received cytotoxic cancer chemotherapy containing platinum with or without Immune Checkpoint Inhibitor (ICI)

Observational, prospective study to examine association values of Interferon-Gamma Release Assay (IGRA) before and after treatment and clinical response or adverse events in patients with lung cancer who received cytotoxic cancer chemotherapy containing platinum with or without Immune Checkpoint Inhibitor (ICI) - Observational, prospective study to examine association values of Interferon-Gamma Release Assay (IGRA) before and after treatment and clinical response or adverse events in patients with lung cancer who received cytotoxic cancer chemotherapy containing platinum with or without Immune Checkpoint Inhibitor (ICI)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037308

Enrollment

Registered

2019-07-10

Start date

2019-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient who received ICI plus chemotherapyor platinum doublet alone as first-line regimen. But, molecular targeted therapy alone and monotherapy of immune checkpoint inhibitor are permitted as prior treatment. 2. Patient with recurrence lung cancer or unresectable progression caner. 3.Diagnosis of small cell lung cancer or the non-small-cell lung cancer 4.Patient was 20 years oldor morehe at registration. 5. Patient with Performance Status 0-2. 5. Patient with the evaluable lesion. 6. Written informed consent was obtained from the patient

Exclusion criteria

Exclusion criteria: 1 Patient with synchronou or metachronous lung cancer

Design outcomes

Primary

Measure	Time frame
Correlation between values of Interferon-Gamma Release Assay and immune related adverse events or efficacy in patients treated with cytotoxic chemotherapy with or without immune checkpoint inhibitor	—

Countries

Japan

Contacts

Public ContactHidekazu Suzuki

Department of Thoracic Oncology, Osaka Habikinol Medical Center Thoracic Oncology

suzukih@ra.opho.jp0729572121

Outcome results